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Background: Intensity modulated radiotherapy (IMRT) is being used to treat carcinoma of
cervix (Ca Cx). Integral dose to normal tissue and increased leakage are the concern about
IMRT. 6MV photon beam is a good choice of energy for Ca Cx IMRT treatment.
Aim: The objective of this study was to compare intensity modulated radiotherapy (IMRT)
plans generated by 6MV and 15MV photon energies for carcinoma of cervix (Ca Cx) with
regards to dosimetric parameters of planning target volume (PTV) and organs at risk (OAR),
homogeneity index (HI), conformity index at 98% level (CI 98%), integral dose to normal
tissue (NTID) and total number of monitor units (MUs).
Material and methods: A cohort of 16 patients was selected for this study. All patients were to
receive a dose of 50Gy in 25 fractions. IMRT plans were generated for both energies using
same dose–volume constraints.
Results: Our results show a comparable coverage of planning target volume (PTV) for both
energies. Volume of PTV receiving a prescription dose is 97.8±0.5% and 98.8±0.4% for
the 6MV and the 15MV plans. Volume of PTV receiving a dose of 107% is 4.4±7.8% and
16.1±22.2%. Bladder and rectummean doses for the 6MV and the 15MV photon plans were
39.8±3.0Gy and 40.0±3.2Gy, and 35.8±3.1Gy and 36.0±3.1Gy, respectively. Homogeneity
index (HI) for both energies was 1.04. The conformity indices at 98% isodose (CI 98%) were
1.3±0.1 and 1.4±0.1 for 6MV and 15MV photon plans, respectively.
Conclusions: We conclude that a 6MV photon is a good choice for Ca Cx IMRT as it produces a
mogehighly conformal, ho© 2010 Greater Poland
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1. Introduction
Carcinoma of cervix (Ca Cx) is a common gynecological can-
cer among women around the world.1 Radiation therapy has
a long history in the treatment of Ca Cx. Three-dimensional
conformal radiotherapy (3DCRT) for Ca Cx had been com-
monly delivered through a four-ﬁeld beam arrangement untill
intensity modulated radiotherapy (IMRT) came into practice.
3DCRT for carcinoma of cervix is most commonly deliv-
ered with high-energy photons. IMRT is an advanced form
of a conformal radiation therapy. It conforms the prescrip-
tion radiation dose to the shape of target tissue in three
dimensions resulting in the sparing of normal surround-
ing tissues.2 IMRT involves multiple beams from different
directions having nonuniformﬂuences. These beams are opti-
mized to deliver a high dose to the target volume and an
acceptably low dose to the surrounding normal structures.
Sparing the surrounding normal tissue may reduce the risk of
toxicity.
It has been shown that IMRT signiﬁcantly reduces the vol-
umeof normal tissues irradiated to high doses in patientswith
gynecologic tumors.3,4 IMRT is increasingly being used nowa-
days in cervical cancer since several studies have reported
its dosimetric and clinical beneﬁt over a conventional whole
pelvis external beam radiotherapy.5–7 In IMRT, total numbers
of monitor units (MUs) are two to three times higher than in
the conventional radiotherapy. That raises the concern about
leakage radiation and secondary malignancy.8,9 Huq et al.10
showed a 40% increase in leakage between the leaves with
high-energy photons (25MV) compared to low energy (6MV);
the measured average leakage was 2.5% and 3.5% for 6MV
and 25MV, respectively. Higher leakage may lead to a higher
dose to the patient outside the irradiated volume. The concern
about leakage and secondarymalignancymakes photon beam
energy an important parameter to be selected during IMRT
planning.11 We have generated IMRT plans using low energy
photons aswell as high-energy photons. In this paper,wehave
studied the effect of beam energy on the quality of IMRT plans
for Ca Cx. This paper investigates whether 15MV beam IMRT
offers a better target coverage and normal tissue sparing than
6MV. Dosimetric parameters of target and OAR used for the
comparison were mean dose, maximum dose, homogeneity
index (HI), conformity index at 98% isodose level (CI 98%),
integral dose to normal tissue (NTID), dose outside the tar-
get and total number of MUs for the plans generated for both
energies.
2. Materials and methods
2.1. Patients characteristics
In this study we compared and evaluated the treatment
plans in terms of dosimetric parameters using 6MV and
15MV photons for Ca Cx patients of different stages (II
to III B). A cohort of 16 patients was selected retrospec-
tively, who received treatment with 3DCRT or IMRT for Ca
Cx. The median anterior-posterior and right–left separa-
tion, of the patient body, for the cohort was 21.0±2.9 cmiotherapy 1 5 ( 2 0 1 0 ) 125–131
(ranging from 15cm to 27.0 cm) and 34.0±4.1 cm (ranging
from 28.6 cm to 41.9 cm), respectively. Median PTV volume
was 981.8±290.3 cm3 (ranging from 648.6 cm3 to 1804.7 cm3).
The rectum and bladder volumes were 83.5±37.6 cm3
(ranging from 37.0 cm3 to 152 cm3) and 144.7±80.9 cm3
(ranging from 66.1 cm3 to 332.5 cm3) respectively. We have
found that a part of bladder and rectum is overlap-
ping with PTV. We have calculated the non-overlapping
volume of bladder (Bladder minus PTV) and rectum (Rec-
tum minus PTV). The Bladder minus PTV volume was
98.1±58.6 cm3 varying from 26.9 cm3 to 226.6 cm3. Rectum
minus PTV volume was 60.8±30.7 cm3 varying from 20cm3
to 117 cm3.
2.2. Simulation, target and OAR delineation
CT simulation was done for all the patients in supine posi-
tion. All patients were immobilized with a thermoplastic
cast (Orﬁt Industry, Belgium). CT scans of each patient were
obtained in the treatment position using LightSpeed VCT
64 slice CT scan (GE Medical Systems, LLC, Waukesha, WI,
USA). CT scans were obtained at 2.5mm slice thickness. The
CT scans were obtained from the L2 vertebral body to 5 cm
below the ischial tuberosities, which is consistent with other
researchers.6 All patients were CT scanned with full bladder.
All patients were simulated, planned and treated in a similar
manner. All structures, gross target volume (GTV), clinical tar-
get volume (CTV), planning target volumes (PTV) weremarked
by radiation oncologist using ICRU recommendations.12 Inter-
observer variability of contouring was not considered in this
study. A uniformmargin of 0.5 cmwas used to create PTV from
CTV expansion. Li et al.13 recommended the use of 0.83 cm
as a CTV–PTV margin for pelvic tumors (including prostate
and gynecologic malignancies) based on mega voltage cone
beam CT (MVCT) imaging. Santanam et al.14 used a margin
of 0.7 cm for gynecological malignancy. Mundt et al.7 used
1 cm PTV margin which greatly increased the volume of nor-
mal tissue irradiated. They found that upper and lower body
immobilization may allow smaller PTV expansion resulting
in a less normal tissue irradiation. Reduction in CTV to PTV
expansion can be accomplished through an improved immo-
bilization and the use of online imaging.15 As we use pelvic
immobilization and kilovoltage (kV) imaging and cone beam
computed tomography (CBCT) for our patient’s setup, and it
is a known fact that the kV imaging has superior soft tissue
contrast,16 we have taken a 0.5 cm margin to create PTV. Rec-
tum, bladder, small bowl and both femoral headsweremarked
as organs at risk (OAR). A non-overlapping structure for blad-
der (Bladder minus PTV) and rectum (Rectum minus PTV) was
created using Boolean operation during structure delineation
to optimize the dosimetry. To evaluate the dose to normal tis-
sues (NT), a structure NT, consisting of non-PTV tissue, was
created by contouring all the tissue within the external skin
contour of the patient.
2.3. Treatment objective and planningAll patients were planned to a total dose of 50Gy in 25 frac-
tions. Our goal was to cover 98% PTV volume to 98% of the
prescription dose. Dose to rectum and bladder was restricted
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n such a way that <40% volume should receive a dose of
0Gy.6 Dose to both femoral heads were restricted, the maxi-
um dose is <50Gy and V45<10%, “i.e.” not more than 10% of
ither femoral head volume should receive a dose of 45Gy.
linically acceptable plans were generated on Eclipse (Ver-
ion 8.5) inverse treatment planning system (Varian Medical
ystems, Concord, Palo Alto, USA) using a pencil beam con-
olution dose calculation algorithm, for both energy levels.
ields were selected so that all the entrance and exit beams
ere evenly spaced around the patients. We have used seven
venly spaced beams at a gantry angle of 0, 51, 102, 153, 204,
55 and 304. Beam arrangement and dose constraints were
he same for all the plans so that we can elucidate the impact
f using different energies. During optimization of the 15MV
lan it was obvious that the modiﬁcations of the objective,
onstraints and respective weights might have resulted for
articular patients in a clinically improved plan, but we did
ot change any parameters in order to maintain the opti-
um plan comparability with 6MV. Normal tissue objective
as used during optimization to reduce hotspots outside PTV.
e have not tried to spare bonemarrow. Due to the retrospec-
ive nature of this study none of the IMRT plan was actually
elivered. The delivery of the treatment plan was simulated
sing a dynamic multileaf collimator (DMLC) of actual beam
ata of a Trilogy Tx accelerator equipped with 120 millenium
LC.sagittal views for 6MV and 15MV plans.
2.4. Dose reporting and evaluation
We have evaluated PTV coverage by computing V47.5, V49,
V50, V53.5 and V55, which is the volume of PTV receiving
47.5Gy, 49Gy, 50Gy, 53.5Gy and 55Gy of dose.
We have evaluated the homogeneity index (HI), and it was
deﬁned as the ratio of dose received by 5% volume of PTV
(lower index) to 95%volume (upper index), “i.e.”D5/D95,where
D5 (lower index) and D95 (upper index) are the doses received
by the 5% and 95% volume of the PTV.
Conformality of high dose around the target was evalu-
ated by calculating the conformity index (CI) at a given isodose
level, e.g. 98% (CI 98%). CI was deﬁned as the ratio of the vol-
ume of total tissue receiving the reference dose to the volume
of PTV.
CI 98% = Volume within 98% isodose line
Volume of PTV
(1)
Rectum and bladder were evaluated for mean dose and V40,
where V40 is the volume of rectum and bladder which is
receiving a dose of 40Gy. Femoral heads were evaluated for
maximum dose and V45, “i.e.” volume of femoral head receiv-
ing 45Gy dose.
To ﬁnd the dose to normal tissues outside the PTV, integral
dose to normal tissue (NTID) was calculated. NTID was calcu-
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for b
their conformality of the radiation dose. PTV dosimetry data
are given in Table 1. Bladder, rectum and femoral head dosi-
metric data regarding mean dose, V40 and V45 are given in
Table 2.
Table 1 – PTV dosimetry parameters.
PTV 6MV 15MV
Mean SD Mean SD
Mean dose (Gy) 52.24 0.35 52.59 0.51Fig. 2 – DVH for PTV and other critical structures are shown
lated manually and deﬁned as a mean dose times the volume
of the structure.
NTID = mean dose × volume (2)
NTID has no signiﬁcance during optimization. NTID was cal-
culated to evaluate the quality of the plan. A two-tailed t-test
was used to compare the data of the two energies. A value of
p<0.05 was considered statistically signiﬁcant.
3. Results
Comparison of plans using 6MV and 15MV photon intensity
modulated beam were carried out for a cohort of 16 patients.
3.1. Isodose distribution
Virtual inspection of isodose surrounding the target was com-
parable. The 6MV plans have shown a slightly sharper dose
gradient than the 15MV plans. To reduce the risk of sever
toxicity, no plan was accepted with a hot spot along the blad-
der and rectal walls as these areas will get a considerable
amount of radiation dose during intracavitary brachyther-
apy. The dose distribution for a patient along axial, coronal
and sagittal planes are shown in Fig. 1 for the 6MV and theoth 6MV and 15MV photon beams of the same patient.
15MV plans respectively. The dose volume histograms (DVH)
for PTV and other critical structures are shown in Fig. 2 for
both the 6MV and the 15MV photon beams of the same
patient.
3.2. Dose volume histogram analysis of PTV and OAR
DVH were calculated for target volume and organ at risk. The
small differences indicate that the plans are nearly identical inV47.5 99.66 0.15 99.79 0.14
V49 99.02 0.25 99.44 0.26
V50 97.82 0.50 98.8 0.43
V53.5 4.45 7.81 16.1 22.18
V55 0 0 0.53 1.81
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Table 2 – Dosimetric data of bladder, rectum and both femoral heads.
Structures 6MV 15MV p-Value
Mean SD Mean SD
Bladder
Mean dose (Gy) 39.84 3.06 40.07 3.17 0.837
V40 (%) 55.71 11.54 56.85 11.20 0.779
Rectum
Mean dose (Gy) 35.80 3.15 36.01 3.15 0.851
V40 (%) 47.09 8.06 47.97 7.83 0.754
Left femoral head
Dmax (Gy) 47.65 1.88 48.37 1.63 0.257
V45 (%) 1.91 2.66 2.70 3.38 0.470
Right femoral head
Dmax (Gy) 46.04 4.90 46.78 4.78 0.669
V45 (%) 1.64 2.04 2.29 2.65 0.443
Table 3 – Plan comparison parameters.
Parameters 6MV 15MV p-Value
Mean SD Mean SD
HI 1.047 0.006 1.042 0.007 0.05
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CI 98% 1.29 0.10
NTID 261.45 61.74
.3. Homogeneity, conformity index and integral dose
omogeneity index (HI) for both energies is 1.04. The target
ose conformity is determined by comparing the volume of
he PTV with the volume encompassed by the 98% isodoses
urface. Our results show that the CI 98% for the 6MV photon
s slightly better than for 15MV, “i.e.” the 6MV photon plans
re able to produce sharper and tight dose distribution around
he PTV. The 15MV photon plan delivers 11.3±2.1% less MUs
han the 6MV photon plans. NTID is calculated using Eq. (2).
esults are shown in Table 3. We found that the 6MV photon
lans deliver 3.1±1.9 higher NTID in comparison to the 15MV
hoton. The mean CI 98% was 1.3±0.1 and 1.4±0.1 for the
MV and the 15MV photon plans, respectively, which is not
tatistically signiﬁcant.
. Discussion
he present study does not show any signiﬁcant difference
etween the 6MV and 15MV photon energies for any of the
valuated parameters.Wehave found that the 6MVand 15MV
lans are comparable in terms of target coverage and critical
tructure sparing. ICRU 50 recommends a uniform dose to the
arget volumewithin−5% to 7%of the dose prescribed.12 How-
ver, a ±10% variation from the prescription is an acceptable
orm in most clinical practice and is widely used in IMRT.17
oeske et al.5 and Mundt et al.7 reported that 110% and 115%
f the prescription dose should be <20% and 2% respectively.
ell et al.18 described a tighter dose limit to PTV where 110%
nd 115% of the prescription dose should be <10% and <1%,
espectively. We have not evaluated 115% isodose in either
lan. There is no isodose of 110% of the prescription dose for1393.5 280.41 0.106
1.35 0.11 0.168
253.21 57.69 0.699
the 6MVphoton, however the 15MVphoton does deliver 110%
dose in 19%patients. Volume of PTV receiving a dose of 53.5Gy
(V53.5) is 4.5±7.8% and 16.1±22.9% for the 6MV and 15MV
photon plans, respectively, which is not statistically signiﬁ-
cant (p-value 0.056). Volume of PTV receiving a dose of 49Gy
(V49) is 99.0±0.3% and 99.4±0.3% for 6MV and 15MV photon
plans, respectively, and it is not statistically signiﬁcant. Blad-
der mean dose is 39.8±3.1Gy and 40.1±3.2Gy for 6MV and
15MV photon plans, respectively. Volume of bladder receiving
a dose of 40Gy (V40) is 55.8±11.5% and 56.9±11.2% for the
6MV and 15MV beams, respectively. It is higher than reported
by Mundt et al.,5 however, they prescribed 45Gy dose to PTV
and we prescribed 50Gy. Rectum mean dose is 35.8±3.1Gy
and 36.0±3.2Gy for the 6MV and 15MV, respectively. Volume
of rectum receiving a dose of 40Gy (V40) is 47.1±8.1% and
48.0±7.9% for the 6MV and 15MV photon plans, respectively.
It is higher than reported by Mundt et al.,6 due to aforemen-
tioned reason. Bladder and rectum doses are not statistically
signiﬁcant for the 6MV and 15MV photon energies.
HI for both energies is 1.04. The mean conformity index (CI
98%) was 1.3±0.1 and 1.4±0.1 for the 6MV and 15MV, respec-
tively, and it was not statistically signiﬁcant. These small
differences indicate that the plans are nearly identical in their
conformity of dose to the target, however, the 6MV photon
plans are slightly superior to the 15MV photon plans, “i.e.”
spillage of high dose outside PTV is lower in the 6MV photon
plans.
D’Souza andRosen19 calculatedNTID for prostate case con-
sidering that it has uniform density. We have also assumed
that the NT has uniform density for the ID calculation. We
found that a low entrance dose for the 15MVbeamwas almost
compensated by a high exit dose even for a very large patient.
Aoyama et al.20 had similar ﬁndings and they concluded that
d rad
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a reduced integral dose from the buildup portion is limited
by a higher exit dose and there is a need for a larger beam
area to accommodate the wider penumbra of the high-energy
beam. It has been reported that the increase in NTID, due to
multiple beam radiation therapy, is a potential risk factor for
the development of secondary malignancies.9,21 Followill et
al.22 made an estimation of the whole body dose equivalent
resulting from IMRT. They concluded that, comparedwith con-
ventional radiotherapy, IMRTmaymore thandouble the risk of
secondary cancers from 0.4% to 1%. These ﬁgures are applied
to a 6MV photon beam while estimates were much higher for
18MV and for tomotherapy. IMRT is likely to double the inci-
dence of second malignancies compared with conventional
radiotherapy from about 1% to 1.75% for patients surviving 10
years. The incidence of radiation induced secondary malig-
nancy are rare though. There aremultiple sources of leakage of
radiation dose to patient, secondary neutron dose to patient,
leakage through primary collimator, leakage through MLC.
Leakage through MLC will add substantially to NTID.20 This
risk becomes more pronounced at higher photon energies
where there is neutron production.We found in our study that
6MV delivers 3.1±1.9% higher NTID. Our data is consistent
with D’Souza and Rosen,19 Aoyama et al.20 and Pirzkall et al.23
Das and Kenneth24 demonstrated that there is no sig-
niﬁcant improvement in the dose distribution and integral
dose ratio for photon energy above 15MV. Sternick et al.25
showed that in treating prostate with rotational IMRT there
was no difference in dose distribution for energies ranging
from 4MV to 18MV. Soderstrom et al.26 demonstrated that
the use of an optimized intensity modulated photon beam
signiﬁcantly reduce the need of beam energy selection. Sola-
iappan et al.27 reported that the percentage dose received
by the 15% volume of rectum and bladder were higher for
10MV photon energy. Sun and Ma28 reported that 6MV plans
deliver 18% more MU than 18MV plans. In our study, the 6MV
photon plans delivered 11.3±2.1%moreMUs than 15MV pho-
ton plans, which is slightly better than reported by Sun and
Ma28 In theory, the increased treatment time can be compen-
sated by increasing the dose rate and the number of MUs can
be reduced by smoothing the ﬂuence without compromising
the quality of plan,29,30,31 although the ratio of MUs remains
the same for 6MV and 15MV plans. New modalities, such
as the volumetric intensity modulated radiotherapy, have the
potential to reduce the MUs and treatment time to less than
2min.32
5. Conclusion
The study was a comparative dosimetric evaluation of 6MV
and 15MV photon beam IMRT plans for Ca Cx. We found that
6MV plans produce relatively less hot spots than 15MV plans,
although the clinical impact of these dosimetric improve-
ments remain unanswered. Our results revealed that, there
is no clinical advantage of 15MV over 6MV in terms of target
coverage and normal tissue sparing. Our study has shown the
feasibility of achieving the desired dose distributionwith 6MV.
We conclude that 6MV photon energy is a good choice for Ca
Cx IMRT.iotherapy 1 5 ( 2 0 1 0 ) 125–131
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